Loading Events

« All Events

5th Wet AMD Diabetic Eye Disease Drug Summit

March 18 - March 20

With Merck’s acquisition of EyeBio for $1.3 Billion, Roche’s Vabysmo launch success and multiple other phase II and III trials in DME, DR, RVO, and Wet AMD, there is plenty to discuss in the retinal vascular drug space as drug developers seek to new alternatives to anti-VEGF, explore biosimilars, and target retinal fibrosis and more to find truly transformative drugs for patients.

The 2025 Wet AMD & Diabetic Eye Disease Summit is set to be an essential meeting for industry leaders, research innovators, and clinical experts dedicated to transforming the landscape of retinal vascular disease treatments.

What’s New for the 2025 Wet AMD & Diabetic Eye Disease Drug Summit?

  • New Strategies for Retinal Vascular Drug Clinical Trials: Delve into advanced strategies for designing clinical trials in Wet AMD and diabetic eye disease, focusing on patient-specific factors and adaptive trial models with insights from Bayer and Aviceda Therapeutics
  • Emerging Biomarker Approaches Wet AMD, DR. DME & RVO: Explore the critical role of biomarkers and clinical endpoints in developing therapies for neovascular retinal disorders, featuring discussions from Opus Genetics and Ocugen
  • Innovative Oral Anti-Inflammatory Treatments for Diabetic Eye Disease: Discover how InflammX Therapeutics is addressing the unmet need in DR and DME patients non-responsive to anti-VEGF therapy with their once-daily oral small molecule
  • Advancements in Retinal Drug Delivery: Discover the benefits of suprachoroidal TKI delivery for Wet AMD with Clearside Biomedical, and hear from Sanofi about incorporating drug delivery devices to improve physician efficiency and patient compliance
  • Breakthroughs in Wet AMD Gene Therapy: Learn about emerging gene therapies for Wet AMD, focusing on innovative approaches and potential impact on patient care with HuidaGene Therapeutics Doheny Eye Centers

Join 50+ biopharma experts from clinical, medical, regulatory. value and access departments from Bayer, Sanofi, EyePoint, Ocular Therapeutix, Clearside Biomedical, RevOpsis, Opus Genetics, and HuidaGene Therapeutics as they accelerate towards releasing longer-lasting, non-invasive and more effective drugs for retinal disease patients.

To know more visit: https://ter.li/sew767

Details

Start:
March 18
End:
March 20

Organizer

Hanson Wade
Phone
UK: +44 (0)20 3141 8700 US: +1 617 455 4188
Email
info@hansonwade.com
View Organizer Website

Venue

Revere Hotel Boston Common
200 Stuart Street
Boston, 02116 United States
+ Google Map